The Use of ctDNA MRD in Clinical Development
Time: 9:30 am
day: Day Two
Details:
- Backed by >50 peer reviewed publications and >200 congress presentations, Signatera’s prognostic and predictive capabilities has been demonstrated across tumor histologies
- Signatera has been shown to identify high-risk patients who may benefit from investigational/novel therapies; more interventional trials are needed for these populations
- Rapid growth in Signatera utilization, especially in colorectal, breast, and bladder cancers, offers a unique opportunity to leverage real-world data for insights into molecular persistence and relapse, as well as clinical trial matching
